TECHWIRE 30
(CIX: WRAL30)  1,219.26  up arrow+15.1  (1.25 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: Apple)  130.28  up arrow+0.61  (0.47 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: QUINTILES)  69.09  up arrow+1.4  (2.07 %)  Updated: 06:40 PM EDT, Apr 24 2015
(OP: BASF SE)  99.39  up arrow+1.28  (1.3 %)  Updated: 05:20 PM EDT, Apr 24 2015
(NQ: BioCryst)  10.35  down arrow-0.18  (-1.71 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: BioDelivery)  9.26  up arrow+0.05  (0.54 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: CEMP)  39.02  up arrow+0.23  (0.59 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: Cisco Systems)  28.82  up arrow+0.15  (0.51 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: Cree)  31.87  down arrow-0.36  (-1.12 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: DARA)  0.81  up arrow+0.04  (5.19 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: EMC CORPORATION)  26.50  down arrow-0.09  (-0.34 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NQ: Extreme Networks)  2.55  down arrow-0.02  (-0.78 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: FB)  81.53  down arrow-0.88  (-1.07 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: GLAXOSMITHKLINE)  46.59  up arrow+0.28  (0.6 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NQ: GOOG)  565.06  up arrow+18.06  (3.3 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: IBM)  169.78  down arrow-0.46  (-0.27 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NY: LH)  126.93  up arrow+0.55  (0.44 %)  Updated: 06:40 PM EDT, Apr 24 2015
(OP: Lenovo Group)  33.55  down arrow-0.18  (-0.53 %)  Updated: 05:20 PM EDT, Apr 24 2015
(NY: MRK)  57.60  up arrow+0.09  (0.16 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NQ: Microsoft Corp)  47.87  up arrow+4.53  (10.45 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: NTAP)  36.12  down arrow-0.17  (-0.47 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: NOVARTIS AG)  104.28  down arrow-1.22  (-1.16 %)  Updated: 06:40 PM EDT, Apr 24 2015
(OP: Novozymes A/S)  47.21  down arrow-0.64  (-1.34 %)  Updated: 05:20 PM EDT, Apr 24 2015
(NY: PFIZER)  35.27  down arrow-0.09  (-0.25 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NQ: Pozen)  8.40  up arrow+0.08  (0.96 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NY: RED HAT)  76.83  down arrow-0.02  (-0.03 %)  Updated: 06:40 PM EDT, Apr 24 2015
(NQ: BBRY)  10.38  up arrow+0.11  (1.07 %)  Updated: 08:10 PM EDT, Apr 24 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  15.65  down arrow-0.35  (-2.19 %)  Updated: 08:10 PM EDT, Apr 24 2015

Posts tagged “GSK”

9:53 a.m. Friday

GSK malaria vaccine nearer OK; Aerie not giving up on glaucoma treatment; Duke Energy's Greentech award; Novartis soars; CDC's new tech tracks listeria

Bulldog In the latest wrapup of technology and life science news: GSK's malaria vaccine is closer to approval after clinical trial; Aerie Pharmaceuticals not giving up on glaucoma treatment; Duke Energy wins a Greentech award; Novartis soars in wake of GSK, Eli Lilly deals; CDC uses new tech to track listeria illnesses.

April 16

Report: GSK shutting Pittsburgh office, eliminating 274 jobs

Layoffs       Drug giant GlaxoSmithKline, which already is cutting hundreds of jobs in the Triangle and in the Philadelphia area, is now in the process of closing an office in Pittsburgh where 274 people work, according to the Pittsburgh Business Times.

April 13

GSK considers revamping compensation plan for sales force

GSK   Drug giant GlaxoSmithKline is considering making changes in the way its sales force is compensated, according to an internal memo obtained by Bloomberg News and The Wall Street Journal.

April 3

GSK picks Maryland for vaccine research and development center

Drug giant GlaxoSmithKline, which is laying off hundreds of people in Research Triangle Park and Pennsylvania, is going to build a new research and development center for vaccines in Maryland.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

Updated March 25

Premium Lock Google Fiber expands; Jim Goodnight's venture play; non-GMO food label; new Instagram app; GSK's next HQ in Asia

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Google Fiber is expanding; Jim Goodnight's new venture play is biotech; a proposed label for non-GMO foods; Instagram has a new app; and GSK is building a new Asian headquarters.

March 25

Premium Lock Life beyond GSK: The entrepreneurial career options

Biotech   At an event put on by the North Carolina Biotechnology Center and supported by GlaxoSmithKline, more than 300 people who are losing their jobs at GSK through layoffs gathered to hear about possible options for future employment. "There is life beyond GSK," former GlaxoWellcome CEO Robert Ingram tells the crowd.

Updated March 23

Premium Lock Glaxo plans 180 layoffs in Durham

GSK's HQ in London GlaxoSmithKline notified the state Monday that it plans to eliminate 180 jobs at its Durham offices effective June 1.

Tags: Layoffs, GSK
March 20

Premium Lock Despite Bill Gates' warning, will world prepare for the next Ebola?

Bill Gates The Bill & Melinda Gates Foundation took a major role in trying to find a vaccine to treat Ebola, even providing funding to Durham-based Chimerix. Now, Bill Gates is warning that the world must prepare for future epidemics. If we are smart, we will listen and learn from what's happened from an outbreak that has killed some 10,000 people.

March 20

Premium Lock AT&T's $40M error; GSK job cuts; Amazon 1-hour delivery; Salix $78M parachutes; GSK inhaler; China freedom group attacked

Bulldog In today's Bulldog wrapup of technology and life science news: AT&T takes a $40M hit in a lawsuit; GSK is cutting 150 jobs in Pa.; Amazon expands 1-hour delivery service; Salix handing out $78M in golden parachutes; GSK wins OK for inhaler; and a China web freedom group is under attack.

March 19

Premium Lock GSK exec: 'Social responsibility' led to Ebola project

Ebola A senior executive at troubled drug giant GlaxoSmithKline says "social responsibility" is a major reason for its attempts to develop a vaccine to treat Ebola. Resources were diverted from other projects to support the Ebola fight, he says.

March 18

Premium Lock GSK invests $25M in global Alzheimer's venture fund

Brain power  GlaxoSmithKline, Biogen, other major drugmakers, the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or even a cure for the mind-robbing disease within a decade.

Updated March 17

Premium Lock Blackberry-IBM-Samsung secure tablet; Cablevision-HBO Now; GSK Ebola update; Facebook's buy; Lyft lawsuit

Bulldog In today's wrapup of technology and life science news: BlackBerry joins with IBM and Samsung to develop a secure tablet; GSK's Ebola vaccine advances; Cablevision hooks up with HBO Now; Facebook's latest buy; and did Lyft cheat drivers?

March 2

Premium Lock GSK, Novartis wrap up $21B asset swap, form joint venture

Drug giants GlaxoSmithKline and Novartis say they have formally closed on a deal valued at more than $21 billion to changes each company in dramatic fashion. Plus, they are moving ahead with a joint venture focusing on consumer healthcare.

A GSK-Novartis joint venture targets over-the-counter products A GSK-Novartis joint venture targets over-the-counter products

Updated February 25

Premium Lock Reddit, Google crack down on nude photos; GSK-Novartis deal nears close; Apple loses $539.M dispute; INC's first results; honor for Quintiles

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Reddit and Google are cracking down on nude photos; GSK says Novartis deal nears close; Apple loses a big patent verdict; INC reports results; an honor for Quintiles.

Updated February 25

Premium Lock GSK's nonprescription diet pill 'alli' back in stores after recall

"alli" back on sale GlaxoSmithKline's diet pill "alli" is now back in most U.S. stores. The drugmaker voluntary recalled the product last March after finding some packages in stores didn't contain real alli, indicating tampering after shipment.

February 23

Premium Lock GSK-Novartis deal OK'd; Apple's $1.92B data centers; Argos buying HQ; Dish founder bis back; CommScope earnings

Bulldog In today's Bulldog wrapup of technology and life science news: The FTC approves the Novartis-GSK cancer drug deal; Apple plans new data centers in Europe; Argos is buying its new headquarters; Dish founder back as CEO; and CommScope reports a profit.

Updated February 18

Premium Lock As Connelly exits, GSK's Triangle campus shakeout continues

The retirement of Deirdre Connelly as GSK's top North American executive on Monday, the naming of her replacement and new roles for two other senior managers are the latest in a series of changes transforming the drug giant's Triangle operations. We've got the latest update.

GSK's R&D facility in RTP   GSK's R&D facility in RTP

Updated February 18

Premium Lock GSK says Connelly 'made decision' to retire, discloses other changes

In a formal statement, GlaxoSmithKline praises Deirdre Connelly, who was replaced as president of U.S. Pharmaceuticals on Monday by Jack Bailey, another GSK executive. GSK also discloses two other management changes affecting U.S. operations.

GSK Headquarters        GSK Headquarters

Updated February 17

Premium Lock GSK's Deirdre Connelly out as head of US operations

Deirdre Connelly, who oversees GlaxSmithKline's operations in the Triangle from her office in Philadelphia, is retiring and will be replaced by another GSK veteran exec. The changes are effective immediately.

Deirdre Connelly Deirdre Connelly

Updated February 13

Premium Lock View-Master coming back; IBM settles pollution suit; AT&T CEO warns on net netraulity; UBS says GSK now is a 'buy'

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Google, Mattel are bringing back the View-Master; IBM settles a pollution suit in New York; AT&T's CEO warns against Internet regulation; and UBS reverses its rating on GSK stock to "buy."

Techwire Inside Partners
The Skinny: A Blog by Rick Smith